ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1853

Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE

Asiya Chida1, Kevin Cashman1, Scott Jenks2, Louise Hartson1, Youliang Wang1, Quan-Zhen Li Li3,4, Chandra Mohan5 and Ignacio Sanz6,7, 1Medicine, Emory University, Atlanta, GA, 2Rheumatology, Emory University School of Medicine, Atlanta, GA, 3Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 4Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, 5Biomedical Engineering, University of Houston, Houston, TX, 6Rheumatology, Emory University, Atlanta, GA, 7Medicine/Rheumatology, Emory University, Atlanta, GA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: auto-immunity and autoantibodies, B cells, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: IgG antibodies expressing the idiotope for the 9G4 idiotype, the framework-1 hydrophobic patch (HP) of VH4-34, are expanded in SLE and provide a unique model to understand the participation of different autoantigens in the regulation of this disease. In particular the antibodies to single stranded RNA (ssRNA) have been implicated in viral infections in SLE. Here, we sought to understand the contribution of VH4-34 antibodies that bind to ssRNA in the pathogenesis of SLE.

Methods:

A panel of 9G4 + monoclonal antibodies (mabs) was generated from IgD+ CD27- naïve B cells and IgD-CD27+ memory B cells of SLE patients.  A total of 30 monoclonal antibodies, (20 native antibodies and corresponding HP altered mutants) were tested for anti-ssRNA binding by ELISA.  Two representative antibodies with strong ssRNA reactivity were also tested against a proteome auantigen microarray and by immunofluorescence.

Results:

Out of the 30 mabs with diverse antigenic binding patterns, 2 derived from SLE memory B cells (22%) had strong autoreactivity with ssRNA.  These antibodies also bound other Ags including: apoptotic and B cell binding, dsDNA, chromatin, Ribosomal P, and were also positive for ssRNA. These two antibodies were of the IgG3 subclass and were clonally related with a single amino acid difference within the CDR2, and identical CDR3 regions of the heavy chain. Further, the corresponding 9G4- HP mutant of these two abs showed binding to ssRNA albeit with decreased intensity.

Conclusion:

Our preliminary results suggest that the anti-RNA response may be abundant in SLE memory B cells and mediated by expanded clones with a predominance of IgG3 antibodies.  9G4 mutagenesis experiments indicate that, while the HP may influence binding is not determinant of this type of autoreactivity.  These findings are consistent with the lack of ssRNA binding of naïve antibodies and suggests that such autoreactivity is dependent on the conventional antigen binding site and may require somatic hypermutation. Larger studies will be required to understand the structural basis, generation and selection of ssRNA antibodies in SLE.  Such studies will shed light into the role of exogenous and endogenous RNA antibodies to SLE autoreactivity.

This work was supported in part by the following grants from National Institute of Health (NIH): NIH-NIAID: 5R37AI049660-12; NIH-NIAID ACE U19: 1U19AI110483-02; NIH-NIAID P01: 5P01AI078907-05 and Georgia Research Alliance.


Disclosure: A. Chida, None; K. Cashman, None; S. Jenks, None; L. Hartson, None; Y. Wang, None; Q. Z. L. Li, None; C. Mohan, None; I. Sanz, None.

To cite this abstract in AMA style:

Chida A, Cashman K, Jenks S, Hartson L, Wang Y, Li QZL, Mohan C, Sanz I. Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/binding-of-a-novel-igg3-vh4-34-monoclonal-antibody-to-ssrna-in-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/binding-of-a-novel-igg3-vh4-34-monoclonal-antibody-to-ssrna-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology